Arcturus Therapeutics Q2 2024 Earnings Report

Revenues increased to $49.9 million, up from $10.5 million in the same period last year, primarily due to the CSL agreement and advancements in the pandemic flu program.

Total operating expenses were $71.0 million, compared to $65.9 million for the three months ended June 30, 2023.

Net loss was $17.2 million, or ($0.64) per diluted share, compared to a net loss of $52.6 million, or ($1.98) per diluted share in the same period last year.

Cash, cash equivalents, and restricted cash totaled $317.2 million as of June 30, 2024.